How technology platforms allow The Vaccine Group to address animal and human vaccine development gaps

TVG has attracted several grants from UK and US governments that have allowed the development of prototype vaccines for important human health and livestock health diseases. Much has been learnt about the capacity of the platform technologies through these projects and several candidate vaccines are in place. In addition, investor funding has allowed progression of additional vaccines for emerging pandemic diseases, namely ASF and Covid-19. The third aspects of TVG’s success to date is the growing partnership with a commercial animal health company for the development of important swine vaccines, one of which to the proof-of-concept stage. TVG was originally spun out from the University of Plymouth (UoP) in 2017. Our experienced 10-strong team includes three postdocs and is led by Dr Jeremy Salt, who as CEO brings 30 years of experience in the animal health field. The Laboratory is led by Dr Michael Jarvis, TVG’s Chief Scientific Officer. Michael has spent his career as an academic researching the manipulation of the herpesvirus genome for the development of vectored vaccines. He holds a joint position with the University of Plymouth, UK as an Associate Professor of Viral and Immunology. The Company is backed by university IP commercialisation specialist Frontier IP Group plc, the University of Plymouth, and individual private investors. Frontier IP provides strategic support and technical guidance to the Company, including the expertise of Matthew White, Frontier IP’s Chief Commercialisation Officer.